US-China tensions persist; Genmab’s $1.8B ADC bet; New obesity startup in town; ALS drug withdrawal; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We have a busy week­end ahead of us, with the an­nu­al con­fer­ences of both the Amer­i­can As­so­ci­a­tion for Can­cer Re­search and the Amer­i­can Col­lege of Car­di­ol­o­gy in full swing. Be sure to check in on Mon­day for our cov­er­age of the lat­est clin­i­cal da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.